The bile duct cell: A bully or a victim?
Carlo Selmi, Massimo Zuin, M. Eric Gershwin – 20 July 2005
Carlo Selmi, Massimo Zuin, M. Eric Gershwin – 20 July 2005
Robert J. Porte, Stephen H. Caldwell – 20 July 2005
Mostafa K. Mohamed, Mohamed Abdel‐Hamid, Nabiel N. Mikhail, Fatma Abdel‐Aziz, Ahmed Medhat, Laurence S. Magder, Alan D. Fix, G. Thomas Strickland – 19 July 2005 – The incidence of hepatitis C (HCV) infection and associated risk factors were prospectively assessed in a cohort of 6,734 Egyptians from 2 rural villages who were negative for antibodies to HCV (anti‐HCV). Initial and follow‐up sera were tested for anti‐HCV by enzyme immunoassay (EIA), and possible incident cases were confirmed by using the microparticle enzyme immunoassay (MEIA) and tested for HCV RNA.
Avidan U. Neumann – 15 July 2005
Adrian Reuben – 15 July 2005
Gianluca Svegliati‐Baroni, Yutaka Inagaki, Ana‐Rosa Rincon‐Sanchez, Cindy Else, Stefania Saccomanno, Antonio Benedetti, Francesco Ramirez, Marcos Rojkind – 15 July 2005 – Acetaldehyde is fibrogenic and induces the expression of type I collagen genes in hepatic stellate cells. Some of these acetaldehyde‐dependent events are mediated by H2O2 and thus establish a direct connection between oxidative stress and collagen upregulation.
Gregory T. Everson, James Trotter, Lisa Forman, Marcelo Kugelmas, Arthur Halprin, Barbara Fey, Catherine Ray – 15 July 2005 – Patients with advanced hepatitis C virus (HCV) are at risk of death and are candidates for liver transplantation. After transplantation, HCV recurs and may rapidly progress to cirrhosis and graft loss. Treatment is needed to prevent progression of disease and minimize recurrence after liver transplantation.
Neil Kaplowitz – 15 July 2005
Winston Dunn, Patrick S. Kamath, Russell H. Wiesner, W. Ray Kim, Vijay Shah – 15 July 2005